Search results
Author(s):
Abdulah Alrifai
,
Mohamad Kabach
,
Jonathan Nieves
,
et al
Added:
3 years ago
More than 10 million Americans suffer annually from angina.1 For decades, most of the attention has been focused on epicardial coronary artery disease (CAD). In a European registry of 11,000 stable angina patients, 65% of women and 32% of men had no obstructive CAD (<50% stenosis); however, multiple other studies have demonstrated only 30% of patients have significant obstructive epicardial…
View more
Author(s):
Gaku Nakazawa
,
Aloke V Finn
,
Renu Virmani
Added:
3 years ago
Polymer-based sirolimus (Cypher®) and paclitaxel (Taxus®) drug-eluting stents (DES) have reduced rates of restenosis and target lesion revascularization (TLR) compared with bare-metal stents (BMS) and have launched a revolution in the interventional treatment of symptomatic coronary artery disease.1,2 However, this overwhelming enthusiasm has recently been dampened by safety concerns regarding a…
View more
Author(s):
Taiyeb M Khumri
,
Michael L Main
Added:
3 years ago
Ultrasound contrast agents capable of transpulmonary passage following intravenous injection have been commercially available since the 1990s. These agents are microbubbles, which are smaller than red blood cells and persist long enough (due to reduced rate of gas diffusion) to reach the left ventricle (LV).1–3 Ultrasound contrast agent applications included LV cavity opacification, enhancement…
View more
Author(s):
Harshal Patil
,
Michael L Main
Added:
3 years ago
DEFINITY® (Perflutren Lipid Microsphere Injectable Suspension, Lantheus Medical Imaging, North Billerica, MA) received approval for clinical use by the US Food and Drug Administration (FDA) in 2001 for “opacification of the left ventricular cavity and enhancement of left ventricular border delineation in patients with technically difficult echocardiograms.”1 By 2007, it was estimated that two…
View more
Drug-eluting Stent Failures
Author(s):
Neville Kukreja
,
Patrick W Serruys
Added:
3 years ago
Article
Author(s):
Albert Alahmar
,
Anthony H Gershlick
Added:
3 years ago
Drug-eluting stents (DES) have revolutionized the field of interventional cardiology. The US Food and Drug Administration (FDA) is expecting that the total number of DES implanted in 2010 will surpass 5 million worldwide. Although initial results seemed promising, longer-term follow-up in a wider range of patients revealed some concerns. Enhanced platelet aggregation, delayed neointimal growth, a…
View more
Author(s):
Sahar S Abdelmoneim
,
Sharon L Mulvagh
Added:
3 years ago
Several advances in the field of echocardiography have led to improvements in the accuracy of stress echocardiography (SE) and further strengthened its established diagnostic and prognostic role in patients with known or suspected coronary artery disease (CAD). 1,2 In addition to its role in CAD, SE can be used to assess the severity of valvular heart disease and for detection of occult pulmonary…
View more
Author(s):
Jason Chinitz
,
Dorinna D Mendoza
,
Raymond J Kim
,
et al
Added:
3 years ago
Accurate detection of left ventricular (LV) thrombus affects clinical outcomes and therapeutic management, as thrombus provides a substrate for thromboembolic events and a rationale for anticoagulation. Relative risk (RR) for thrombus development is highest among subjects with systolic heart failure or myocardial infarction (MI), reflecting a link between impaired LV blood stasis, pro-coagulant…
View more
Author(s):
Giora Weisz
Added:
3 years ago
Much has been written, but little is known, about the long-term outcomes after drug-eluting stent (DES). The introduction of DES has extended the use of stents from a passive platform for vessel wall scaffolding to an active biotechnology vehicle for local delivery of antiproliferative pharmacotherapy. Like any other therapy or medical technology, no treatment is perfect and free of potential…
View more
Author(s):
Essa Hariri
,
Anna Scandinaro
,
Mazen M Al Hammoud
,
et al
Added:
1 year ago